Conflict of interest
TD, Johnson & Johnson and
ONCOLOGY
MG has served in an advisory capacity for Amgen, Eli Lilly and Company, Merck Pharmaceuticals, Roche, Italfarmaco and Servier Pharmaceuticals. HH reports medical writing support for the submitted work and payment for expert testimony from Taiho Oncology, Inc. TD reports institutional research funding from AbbVie, BMS, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, Eisai, Janssen Pharma, IQVIA, Lilly, Merck Biopharma, MSD, Novartis, Pfizer, Sumitomo Dainippon and Taiho; consulting fees from AbbVie, Bayer, Chugai Pharma, Kaken Pharma, Kyowa Kirin, Otsuka Pharma, Rakuten Medical, PRA Health Science, Shionogi, Sumitomo Dainippon, Takeda and Taiho; honoraria from AstraZeneca, BMS, Daiichi Sankyo, Ono Pharma and Rakuten Medical; and has participated in an advisory role for AbbVie, Amgen, Astellas Pharma, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Janssen Pharma, MSD and Novartis. EVC reports institutional research grants or funding from Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche and Servier; and participation in advisory boards for Abbvie, Array, Astellas, Astrazeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi, Halozyme, GSK, Helsinn, Incyte, Ipsen, Janssen Research, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Pierre Fabre, Roche, Seattle Genetics, Servier, Sirtex, Terumo, Taiho, TRIGR and Zymeworks. LM is a consultant statistician for Taiho Oncology, Inc. and is paid by Taiho Oncology, Inc. OT is a former employee of Taiho Oncology, Johnson & Johnson and AstraZeneca. KAB is an employee at Taiho Oncology, and owns stock of Eli Lilly. WM has served in an advisory capacity for BMS, MSD and Servier, and reports honoraria from Amgen, BMS and MSD for lectures.